This HTML5 document contains 32 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/uniprotkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/genbank/
n9http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00042/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00042
rdf:type
n5:Drug
n5:description
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
n5:dosage
n13:271B4158-363D-11E5-9242-09173F13E4C5 n13:271B4159-363D-11E5-9242-09173F13E4C5 n13:271B415A-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15907915 # Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10534247 # Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15839401 # Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15887434 # Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15928517
n5:group
approved
n5:indication
For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
owl:sameAs
n7:DB00042 n9:DB00042
dcterms:title
Botulinum Toxin Type B
adms:identifier
n4:PA164747061 n18:P10844 n19:M81186 n20:Botulinum_toxin n21:D02735 n23:DB00042
n5:mechanismOfAction
Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.
n5:packager
n8:271B4155-363D-11E5-9242-09173F13E4C5
n5:synonym
Botulinum neurotoxin type B precursor BTX-B
n5:toxicity
One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.
n10:hasConcept
n11:M0253447
foaf:page
n16:botulinumtoxin.htm n17:botulinum-toxin-type-b.html
n5:Molecular-Weight
n14:271B415B-363D-11E5-9242-09173F13E4C5
n5:absorption
Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
93384-44-2
n5:category
n5:containedIn
n12:271B4156-363D-11E5-9242-09173F13E4C5 n12:271B4157-363D-11E5-9242-09173F13E4C5